ATP13A2 levels in serum and cerebrospinal fluid in patients with idiopathic Parkinson's disease

Fernández-Espejo, Emilio; Fonseca, Fernando Rodríguez de; Suárez, Juan; Gonzalez-Aparicio, R.; Santurtún, Ana

doi:10.1016/j.parkreldis.2021.05.014

Cited by 6 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regards the histological study, ATP13A2 was differentially expressed by most cell types in the submandibulary gland. This finding fits well with the ubiquitous bodily distribution of the protein [12] , [13] . Tissue distribution and intensity of ATP13A2 staining seem to be similar in both the patients and controls.…”

Section: Discussionsupporting

confidence: 88%

“…Morbid obesity was diagnosed when BMI was higher than 35 kg/m 2 . In addition, all participants were non-alcohol drinkers, non-smokers, and non-coffee drinkers, according to established criteria [13] , [24] , [25] .…”

Section: Methodsmentioning

confidence: 99%

“…Recently, we examined the association between serum and cerebrospinal fluid (CSF) ATP13A2 levels with clinical features in PD patients [13] . The findings revealed that ATP13A2 concentration in serum, but not in the CSF, positively correlated with the dose intensity of the dopaminergic medication, expressed as levodopa equivalent daily dose (LEDD) [13] . These findings suggest that serum ATP13A2 content might be an index of the intensity of dopaminergic medication in patients with idiopathic PD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease

Fernández-Espejo¹,

Gavito

Suárez

et al. 2022

Clinical Parkinsonism & Related Disorders

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease

Fernández-Espejo¹,

Gavito

Suárez

et al. 2022

Clinical Parkinsonism & Related Disorders

Self Cite

View full text Add to dashboard Cite

“…In addition to NCL, ATP13A2 (also known as PARK9 ) is recognized as one of the key genes that cause a juvenile form of Parkinson's disease called Kufor‐Rakeb Syndrome (KRS), as well as a subtype of hereditary spastic paraplegia called spastic paraplegia 78 (SPG78) (Ban et al, 2021; Di Fonzo et al, 2007; Estrada‐Cuzcano et al, 2017; Martino et al, 2015; Odake et al, 2020; Suleiman et al, 2018). It has also been suggested that ATP13A2 could be used as a biomarker for assessing the response to dopamine replacement therapy in Parkinson's disease (Fernández‐Espejo et al, 2021). Aberrant function of ATP13A2 is associated with α‐synuclein accumulation in lysosomes due to reduced release of α‐synuclein from cells via exosomes (Kong et al, 2014; Tsunemi et al, 2014; Tsunemi & Krainc, 2014).…”

Section: The Networking Of Cln Genes and Proteinsmentioning

confidence: 99%

“…Ward et al (2017);Valdez et al (2017) in Parkinson's disease(Fernández-Espejo et al, 2021). Aberrant function of ATP13A2 is associated with α-synuclein accumulation in lysosomes due to reduced release of α-synuclein from cells…”

mentioning

confidence: 99%

Recent insights into the networking of CLN genes and proteins in mammalian cells

Huber

2023

Journal of Neurochemistry

View full text Add to dashboard Cite

Ceroid lipofuscinosis neuronal (CLN) genes encode 13 proteins that localize throughout the endomembrane system to regulate a variety of cellular processes. In humans, mutations in CLN genes cause a devastating form of neurodegeneration called neuronal ceroid lipofuscinosis (NCL), commonly known as Batten disease. Each CLN gene is associated with a specific subtype of the disease that differ from each other in severity and age of onset. The NCLs affect all ages and ethnicities worldwide but primarily affect children. The pathology underlying the NCLs is poorly understood, which has prevented the development of a cure or effective therapy for most subtypes of the disease. A growing body of literature supports the networking of CLN genes and proteins within cells, which aligns with the broadly similar cellular and clinical manifestations among the different subtypes of NCL. Here, all relevant literature is reviewed to provide a comprehensive overview of our current understanding of how CLN genes and proteins are networked in mammalian cells with an aim toward revealing new molecular targets for therapy development. Intriguingly, CLN gene and protein networking extends beyond the NCLs as recent work has linked several CLN genes and proteins to other forms of neurodegeneration such as Alzheimer's disease and Parkinson's disease. Thus, a deeper understanding of the pathways and cellular processes impacted by mutations in CLN genes will not only strengthen our knowledge of the pathological mechanisms underlying the NCLs but may also provide new insight into related forms of neurodegeneration.

show abstract

Rose essential oil diminishes dopaminergic neuron degenerations and reduces α‐synuclein aggregation in Caenorhabditis elegans models of Parkinson's disease

Muhammad

Liu

Wang

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Parkinson's disease (P.D.) is the second most progressive neurodegenerative disorder in the elderly. Degeneration of dopaminergic (DA) neurons and α-synuclein (α-Syn) accumulated toxicity is the major contributor to this disease. At present, the disease has no effective treatment. Many recent studies focus on identifying novel therapeutics that provide benefits to stop the disease progression in P.D. patients. Screening novel and effective drugs in P.D. animal models is time-and cost-consuming. Rose Essential Oil (REO) extracted from Rosa Rugosa species (R. Setate Â R. Rugosa). REO contains Citronellol, Geraniol, and Octadiene that possess anti-Aβ, anti-oxidative, and anti-depression-like properties, but no reports have defined the REO effect on P.D. yet. The present study examines the REO neuroprotective potential in transgenic Caenorhabditis elegans P.D. models. We observed that REO reduced α-Syn aggregations and diminished DA neuron degenerations induced by 6-OHDA, reduced food-sensing behavioural disabilities, and prolonged the lifespan of the nematode. Moreover, REO augmented the chymotrypsin-like proteasome and SOD-3 activities. Further, we observed the anti-oxidative role of REO by reducing internal cells ROS.Together, these findings supported REO as an anti-PD drug and may exert its effects by lowering oxidative stress via the anti-oxidative pathway.

show abstract

ATP13A2 levels in serum and cerebrospinal fluid in patients with idiopathic Parkinson's disease

Cited by 6 publications

References 28 publications

Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease

Salivary ATP13A2 is a potential marker of therapy-induced motor complications and is expressed by inclusions in submandibulary glands in Parkinson ́s disease

Recent insights into the networking of CLN genes and proteins in mammalian cells

Rose essential oil diminishes dopaminergic neuron degenerations and reduces α‐synuclein aggregation in Caenorhabditis elegans models of Parkinson's disease

Contact Info

Product

Resources

About